Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial

[1]  S. Pinder,et al.  Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. , 2016, Journal of the National Cancer Institute.

[2]  John M S Bartlett,et al.  OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. , 2016, Health technology assessment.

[3]  Peter A Kaufman,et al.  Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer , 2014, Cancer.

[4]  J. Donovan,et al.  Selecting breast cancer patients for chemotherapy: the opening of the UK OPTIMA trial. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[5]  Eunyoung Kang,et al.  Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance , 2012, Modern Pathology.

[6]  I. Ellis,et al.  Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast , 2012, Histopathology.

[7]  J. Bartlett,et al.  HER2 gene amplification in breast cancer: a rogues' gallery of challenging diagnostic cases: UKNEQAS interpretation guidelines and research recommendations. , 2012, American journal of clinical pathology.

[8]  I. Ellis,et al.  HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods , 2011, Journal of Clinical Pathology.

[9]  John M S Bartlett,et al.  Estrogen receptor and progesterone receptor as predictive biomarkers of response to endocrine therapy: a prospectively powered pathology study in the Tamoxifen and Exemestane Adjuvant Multinational trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Dowsett,et al.  Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  P. Fitzgibbons,et al.  National HER2 proficiency test results using standardized quantitative controls: characterization of laboratory failures. , 2009, Archives of pathology & laboratory medicine.

[12]  I. Ellis,et al.  HER2 testing in the UK: further update to recommendations , 2008, Journal of Clinical Pathology.

[13]  R. Tamimi,et al.  Comparison of estrogen receptor results from pathology reports with results from central laboratory testing. , 2008, Journal of the National Cancer Institute.

[14]  P. Neven,et al.  Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Neven,et al.  Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer : BIG 198 , 2007 .

[16]  Peter A Kaufman,et al.  HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Peter A Kaufman,et al.  Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. , 2002, Journal of the National Cancer Institute.

[18]  C K Osborne,et al.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.